CNS Oncology最新文献_第9页

Radiographic appearance of leptomeningeal disease in patients with EGFR-mutated non-small-cell lung carcinoma treated with tyrosine kinase inhibitors: a case series 用酪氨酸激酶抑制剂治疗egfr突变的非小细胞肺癌患者的轻脑膜疾病的影像学表现:一个病例系列

CNS Oncology Pub Date : 2019-06-20 DOI: 10.2217/cns-2019-0010

Ugur T Sener, Nassim Matin, H. Yu, A. Lin, T. Yang, R. Malani

引用次数: 3

Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors. 419例胶质母细胞瘤及其他原发性脑肿瘤患者游离循环肿瘤DNA分析。

CNS Oncology Pub Date : 2019-06-01 Epub Date: 2019-03-11 DOI: 10.2217/cns-2018-0015

David E Piccioni, Achal Singh Achrol, Lesli A Kiedrowski, Kimberly C Banks, Najee Boucher, Garni Barkhoudarian, Daniel F Kelly, Tiffany Juarez, Richard B Lanman, Victoria M Raymond, Minhdan Nguyen, Judy D Truong, Annie Heng, Jaya Gill, Marlon Saria, Sandeep C Pingle, Santosh Kesari

{"title":"Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors.","authors":"David E Piccioni, Achal Singh Achrol, Lesli A Kiedrowski, Kimberly C Banks, Najee Boucher, Garni Barkhoudarian, Daniel F Kelly, Tiffany Juarez, Richard B Lanman, Victoria M Raymond, Minhdan Nguyen, Judy D Truong, Annie Heng, Jaya Gill, Marlon Saria, Sandeep C Pingle, Santosh Kesari","doi":"10.2217/cns-2018-0015","DOIUrl":"https://doi.org/10.2217/cns-2018-0015","url":null,"abstract":"Aim: Genomically matched trials in primary brain tumors (PBTs) require recent tumor sequencing. We evaluated whether circulating tumor DNA (ctDNA) could facilitate genomic interrogation in these patients. Methods: Data from 419 PBT patients tested clinically with a ctDNA NGS panel at a CLIA-certified laboratory were analyzed. Results: A total of 211 patients (50%) had ≥1 somatic alteration detected. Detection was highest in meningioma (59%) and gliobastoma (55%). Single nucleotide variants were detected in 61 genes, with amplifications detected in ERBB2, MET, EGFR and others. Conclusion: Contrary to previous studies with very low yields, we found half of PBT patients had detectable ctDNA with genomically targetable off-label or clinical trial options for almost 50%. For those PBT patients with detectable ctDNA, plasma cfDNA genomic analysis is a clinically viable option for identifying genomically driven therapy options.","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/cns-2018-0015","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37042504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 106

Efficacy and safety of immune checkpoint blockade for brain metastases. 免疫检查点阻断治疗脑转移瘤的疗效和安全性。

CNS Oncology Pub Date : 2019-06-01 Epub Date: 2019-03-11 DOI: 10.2217/cns-2018-0018

Maya Harary, David A Reardon, J Bryan Iorgulescu

引用次数: 18

Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series. 贝伐单抗治疗复发性胶质瘤后的长期生存模式:一个病例系列。

CNS Oncology Pub Date : 2019-06-01 Epub Date: 2019-07-11 DOI: 10.2217/cns-2019-0007

Liang Yen Liu, Matthew S Ji, Nhung T Nguyen, Frances E Chow, Donna M Molaie, Sean T Pianka, Richard M Green, Linda M Liau, Benjamin M Ellingson, Phioanh L Nghiemphu, Timothy F Cloughesy, Albert Lai

引用次数: 5

Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study. 福莫司汀治疗老年复发性胶质母细胞瘤的双周计划：一项多中心研究的活性和毒性评估。

CNS Oncology Pub Date : 2019-06-01 Epub Date: 2019-07-10 DOI: 10.2217/cns-2019-0004

Raffaele Addeo, Giuseppe Lamberti, Giorgia Simonetti, Patrizia Iodice, Alfredo Marinelli, Liliana Montella, Salvatore Cappabianca, Paola Gaviani, Michele Caraglia, Salvatore Del Prete, Antonio Silvani

引用次数: 5

Comparative proteogenomic characterization of glioblastoma. 胶质母细胞瘤的比较蛋白质基因组特征。

CNS Oncology Pub Date : 2019-06-01 Epub Date: 2019-07-10 DOI: 10.2217/cns-2019-0003

Samia Asif, Rawish Fatima, Rebecca Krc, Joseph Bennett, Shahzad Raza

{"title":"Comparative proteogenomic characterization of glioblastoma.","authors":"Samia Asif, Rawish Fatima, Rebecca Krc, Joseph Bennett, Shahzad Raza","doi":"10.2217/cns-2019-0003","DOIUrl":"10.2217/cns-2019-0003","url":null,"abstract":"Aim: Glioblastoma multiforme (GBM) carries a dismal prognosis. Integrated proteogenomic analysis was performed to understand GBM pathophysiology. Patients & methods: 17 patient samples were analyzed for driver mutations, oncogenes, major pathway alterations and molecular changes at gene and protein level. Clinical, treatment and survival data were collected. Results: Significantly mutated genes included TP53, EGFR, PIK3R1, PTEN, NF1, RET and STAG2. EGFR mutations noted included EGFRvIII-expression, EGFR-L816Q missense mutation-exon 21 and EGFR fusion (FGFR3-TACC3). TP53 mutations were noticed in COSMIC hot-spot driver gene and accompany IDH1 and ATRX mutations suggesting low- to high-grade glioma transformation. Proteomics showed higher (53%) EGFR expression than genomic expression (23%). MGMT methylation was present in two-thirds of cases. Conclusion: This study identifies a distinct biological process that may characterize each GBM differently. Proteogenomic data identify potential therapeutic targets of GBM.","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/18/6e/cns-08-37.PMC6713026.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37404356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Shifting paradigms: whole brain radiation therapy versus stereotactic radiosurgery for brain metastases. 转移范式:脑转移的全脑放射治疗与立体定向放射手术。

CNS Oncology Pub Date : 2019-03-01 Epub Date: 2019-01-31 DOI: 10.2217/cns-2018-0016

Ashwin Shinde, David Akhavan, Mina Sedrak, Scott Glaser, Arya Amini

引用次数: 22

An early feasibility study of the Nativis Voyager^® device in patients with recurrent glioblastoma: first cohort in US. native Voyager®设备用于复发性胶质母细胞瘤患者的早期可行性研究:美国第一队列研究

CNS Oncology Pub Date : 2019-03-01 Epub Date: 2018-12-14 DOI: 10.2217/cns-2018-0013

Charles Cobbs, Edward McClay, J Paul Duic, L Burt Nabors, Donna Morgan Murray, Santosh Kesari

{"title":"An early feasibility study of the Nativis Voyager® device in patients with recurrent glioblastoma: first cohort in US.","authors":"Charles Cobbs, Edward McClay, J Paul Duic, L Burt Nabors, Donna Morgan Murray, Santosh Kesari","doi":"10.2217/cns-2018-0013","DOIUrl":"https://doi.org/10.2217/cns-2018-0013","url":null,"abstract":"Aim: Evaluation of the Nativis Voyager® device in patients with recurrent glioblastoma (rGBM).Materials & methods: Voyager is a noninvasive, nonthermal, nonionizing and portable investigational device which delivers ultra-low radio frequency energy (ulRFE®) that uses a magnetic field to penetrate tissues to alter specific biologic functions within cells. Patients with rGBM were treated with Voyager alone (V) or Voyager in combination with standard of care (V + SoC). Safety and clinical utility were assessed every 2-4 months.Results: Data from the first 11 patients treated are reported here. Median progression-free survival was 10 weeks in the V arm and 16 weeks in the V + SoC arm. Median overall survival was 16 months in V arm and 11 months in the V + SoC arm. No serious adverse events associated with the device were reported.Conclusion: These data suggest that the Voyager is safe and feasible for the treatment of rGBM.","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/cns-2018-0013","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36782179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

A case report of high-grade astroblastoma in a young adult. 青年人高级别星形母细胞瘤1例报告。

CNS Oncology Pub Date : 2019-03-01 Epub Date: 2019-02-28 DOI: 10.2217/cns-2018-0012

Sagar Bhalerao, Rajnish Nagarkar, Aditya Adhav

引用次数: 7

How far will the Voyager^® take us? 旅行者号®将带我们走多远?

CNS Oncology Pub Date : 2019-03-01 Epub Date: 2019-02-15 DOI: 10.2217/cns-2018-0019

Victor A Levin

{"title":"How far will the Voyager® take us?","authors":"Victor A Levin","doi":"10.2217/cns-2018-0019","DOIUrl":"https://doi.org/10.2217/cns-2018-0019","url":null,"abstract":"Need for better treatments for glioblastoma Overall survival of people afflicted with glioblastoma (GBM) has improved modestly over the past 30 years and ranges between a median overall survival of 10 and 16 months depending on factors such as age, gender, extent of surgery, molecular-genetic features of resected tumors, radiation therapy and chemotherapy. Treatment options for people afflicted with GBM have changed somewhat based on molecular-genetic profiles that define worst-case scenarios [1–3] and improvements in radiation therapy that have also reduced CNS toxicity somewhat [4]. Based on patient convenience and outcomes, temozolomide has become the major anticancer drug therapy for these tumors [5]. Most recently, chronic treatment with alternating electric tumor treating fields to the head has gained US FDA approval for the treatment of GBM [6,7]. New therapies, especially new chemotherapy drugs, have been limited to brain penetrant alkylating agents (i.e., carmustine, lomustine, and temozolomide) since the 1970s. There are several reasons for this, which relate to drug delivery to infiltrative tumor cells behind the blood–brain barrier (BBB), drug residence time on tumor cell target, appropriateness of cellular target and the need to inhibit more than one cellular target, drug pharmacokinetics and drug safety [8,9].","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/cns-2018-0019","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36561995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1